Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii with vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication
ChiCTR2300075347Phase 4Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Sep 2023
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in Helicobacter pylori infection comparing Control: vonoprazan + amoxicillin with Saccharomyces boulardii + vonoprazan + amoxicillin (2 arms). Primary endpoint: Helicobacter pylori eradication rate. Started Sep 2023; status: recruiting.
02
Drugs
saccharomyces boulardiivonoprazanamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300075347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075347.